Literature DB >> 33544287

Genetic Contribution to Non-alcoholic Fatty Liver Disease and Prognostic Implications.

Katherine Martin1,2,3, Anas Hatab4,5, Varinder S Athwal4,5,6, Elliot Jokl4,5, Karen Piper Hanley7,8.   

Abstract

PURPOSE OF REVIEW: Non-alcoholic fatty liver disease (NAFLD) is a major and increasing health burden, with the potential to overwhelm hepatology services. However, only a minority of patients develop advanced liver disease. The challenge is early identification of patients at risk of progression. This review aims to summarize current knowledge on the genetic predisposition to NAFLD, and its implications for prognostication and risk stratification. RECENT
FINDINGS: PNPLA3-I148M is the most robustly associated genetic variant with NAFLD. Recently, variants in TM6SF2, MBOAT7, GCKR and HSD17B13 have also been implicated. NAFLD is a complex disease, and any one genetic variant alone is insufficient for risk stratification, but combining multiple genetic variants with other parameters is a promising strategy. It is anticipated that, in the near future, analysis of data from large-scale prospective cohorts will reveal NAFLD subtypes and enable the development of prognostic models. This will facilitate risk stratification of patients, enabling optimisation of resources to effectively manage the NAFLD epidemic.

Entities:  

Keywords:  Genetic; Non-alcoholic fatty liver disease; Risk stratification

Year:  2021        PMID: 33544287      PMCID: PMC7864835          DOI: 10.1007/s11892-021-01377-5

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  83 in total

Review 1.  Liver biopsy.

Authors:  A A Bravo; S G Sheth; S Chopra
Journal:  N Engl J Med       Date:  2001-02-15       Impact factor: 91.245

Review 2.  Mechanisms of hepatic fibrogenesis.

Authors:  Scott L Friedman
Journal:  Gastroenterology       Date:  2008-05       Impact factor: 22.682

Review 3.  Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.

Authors:  Siddharth Singh; Alina M Allen; Zhen Wang; Larry J Prokop; Mohammad H Murad; Rohit Loomba
Journal:  Clin Gastroenterol Hepatol       Date:  2014-04-24       Impact factor: 11.382

4.  Comparative proteomic study reveals 17β-HSD13 as a pathogenic protein in nonalcoholic fatty liver disease.

Authors:  Wen Su; Yang Wang; Xiao Jia; Wenhan Wu; Linghai Li; Xiaodong Tian; Sha Li; Chunjiong Wang; Huamin Xu; Jiaqi Cao; Qifei Han; Shimeng Xu; Yong Chen; Yanfeng Zhong; Xiaoyan Zhang; Pingsheng Liu; Jan-Åke Gustafsson; Youfei Guan
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-15       Impact factor: 11.205

5.  Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.

Authors:  Mattias Ekstedt; Hannes Hagström; Patrik Nasr; Mats Fredrikson; Per Stål; Stergios Kechagias; Rolf Hultcrantz
Journal:  Hepatology       Date:  2015-03-23       Impact factor: 17.425

6.  Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum.

Authors:  Yuval A Patel; Joanne C Imperial; Andrew J Muir; Quentin M Anstee; David DeBrota; Lara Dimick-Santos; Claudia Filozof; Ruby Mehta; Arun J Sanyal; Elmer Schabel; Brent A Neuschwander-Tetri; Veronica Miller
Journal:  Gastroenterology       Date:  2017-07-27       Impact factor: 22.682

Review 7.  Non-alcoholic fatty liver disease - A global public health perspective.

Authors:  Zobair M Younossi
Journal:  J Hepatol       Date:  2018-11-09       Impact factor: 25.083

8.  Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.

Authors:  Kerry L Donnelly; Coleman I Smith; Sarah J Schwarzenberg; Jose Jessurun; Mark D Boldt; Elizabeth J Parks
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

9.  Associations of common polymorphisms in GCKR with type 2 diabetes and related traits in a Han Chinese population: a case-control study.

Authors:  Yan Ling; Xiaomu Li; Qian Gu; Hongyan Chen; Daru Lu; Xin Gao
Journal:  BMC Med Genet       Date:  2011-05-13       Impact factor: 2.103

10.  Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci.

Authors:  Stefan Stender; Julia Kozlitina; Børge G Nordestgaard; Anne Tybjærg-Hansen; Helen H Hobbs; Jonathan C Cohen
Journal:  Nat Genet       Date:  2017-04-24       Impact factor: 38.330

View more
  4 in total

1.  Non-Alcoholic Fatty Liver Disease in Long-Term Type 2 Diabetes: Role of rs738409 PNPLA3 and rs499765 FGF21 Polymorphisms and Serum Biomarkers.

Authors:  Mauy Frujuello Mana; Maria Cândida R Parisi; Maria Lucia Correa-Giannella; Arnaldo Moura Neto; Ademar Yamanaka; Marlone Cunha-Silva; Ana Mercedes Cavaleiro; Cristina Rodrigues Dos Santos; Célia Regina Pavan; Tiago Sevá-Pereira; Sergio S J Dertkigil; Daniel F Mazo
Journal:  Molecules       Date:  2022-05-17       Impact factor: 4.927

Review 2.  Nonalcoholic Fatty Liver Disease: Focus on New Biomarkers and Lifestyle Interventions.

Authors:  Maria Notarnicola; Alberto Ruben Osella; Maria Gabriella Caruso; Pasqua Letizia Pesole; Antonio Lippolis; Valeria Tutino; Caterina Bonfiglio; Valentina De Nunzio; Maria Principia Scavo; Antonella Mirizzi; Isabella Franco; Tamara Lippolis; Rosalba D'Alessandro; Maria Grazia Refolo; Caterina Messa
Journal:  Int J Mol Sci       Date:  2021-04-09       Impact factor: 5.923

3.  Genetic variants associated with metabolic dysfunction-associated fatty liver disease in western China.

Authors:  Shenling Liao; Kang An; Zhi Liu; He He; Zhenmei An; Qiaoli Su; Shuangqing Li
Journal:  J Clin Lab Anal       Date:  2022-07-26       Impact factor: 3.124

Review 4.  NAFLD in normal weight individuals.

Authors:  Johanna K DiStefano; Glenn S Gerhard
Journal:  Diabetol Metab Syndr       Date:  2022-03-24       Impact factor: 5.395

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.